VEITH 2019Editor's PickInterviewsEditors Pick HomepagePeripheralEditors Pick PeripheralPeripheral InterviewsLatest news PeripheralLearning AreasEvents Combination of scaffold and drug in BTK intervention “without question” the right way forward
VEITH 2019AorticEditors Pick AorticAortic InterviewsEditor's PickLatest news AorticInterviewsLearning AreasEvents Trials needed to assess whether metformin impedes aneurysm progression in non-diabetic patients
ESMINT 2019Editor's PickInterviewsEditors Pick HomepageNeuroEditors Pick NeuroNeuro InterviewsLatest news NeuroLearning AreasEvents ESMINT 2019: “Vast majority” of people do not expect children to have strokes
Editor's PickInterviewsEditors Pick HomepageNeuroEditors Pick NeuroNeuro InterviewsLatest news NeuroLearning AreasEventsSNIS 2019 SNIS 2019: “Almost unethical” not to broaden thrombectomy inclusion criteria and treat more patients
Editor's PickInterviewsEditors Pick HomepageSpinalLearning AreasEditors Pick SpinalSpinal InterviewsIMAST 2019 IMAST 2019: Industry sponsored disc replacement trials should be treated with “caution”
Editor's PickInterviewsEditors Pick HomepageNeuroEditors Pick NeuroNeuro InterviewsLearning AreasEventsSNIS 2019 SNIS 2019: Next-generation thrombectomy will be “even more powerful”
IRPeripheralEditors Pick PeripheralPeripheral InterviewsLatest news PeripheralVEITHsymposium 2018 PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in PAD treatment
